Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.

被引：0
|
作者：
Dimopoulos, Meletios A.
Voorhees, Peter M.
Goldschmidt, Hartmut
Baker, Ross I.
Shi, Yingqi
Rousseau, Els
Dennis, Robyn Monet
Carson, Robin L.
Rajkumar, S. Vincent
机构：
[1] Natl & Kapodistrian Univ Athens, Athens, Greece
[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[3] Univ Heidelberg Hosp, Internal Med 5, Heidelberg, Germany
[4] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[5] Murdoch Univ, Perth Blood Inst, Perth, Australia
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8075
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
    Rajkumar, S. Vincent
    Voorhees, Peter Michael
    Goldschmidt, Hartmut
    Baker, Ross I.
    Bandekar, Rajesh
    Kuppens, Steven
    Neff, Tobias
    Qi, Ming
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): CENTAURUS
    Cavo, M.
    Hofmeister, C. C.
    Chari, A.
    Cohen, Y. C.
    Spencer, A.
    Voorhees, P.
    Estell, J.
    Venner, C.
    Sandhu, I
    Jenner, M.
    Williams, C.
    van de Donk, N.
    Beksac, M.
    Kuppens, S.
    Bandekar, R.
    Neff, T.
    Heuck, C.
    Qi, M.
    Goldschmidt, H.
    Landgren, Ola C.
    HAEMATOLOGICA, 2018, 103 : 40 - 41
  • [3] Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study
    Hofmeister, Craig C.
    Chari, Ajai
    Cohen, Yael
    Spencer, Andrew
    Voorhees, Peter M.
    Estell, Jane
    Venner, Christopher P.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Cathy
    Cavo, Michele
    Van de Donk, Niels W. C. J.
    Beksac, Meral
    Kuppens, Steven
    Bandekar, Rajesh
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Goldschmidt, Hartmut
    Landgren, Ola
    BLOOD, 2017, 130
  • [4] Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
    Nahi, Hareth
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Yang, Shiyi
    Hellemans, Peter
    Tromp, Brenda J.
    Luo, Man
    Zemlickis, Donna
    Farnsworth, Andrew
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    C. Ola Landgren
    Ajai Chari
    Yael C. Cohen
    Andrew Spencer
    Peter Voorhees
    Jane A. Estell
    Irwindeep Sandhu
    Matthew W. Jenner
    Catherine Williams
    Michele Cavo
    Niels W. C. J. van de Donk
    Meral Beksac
    Philippe Moreau
    Hartmut Goldschmidt
    Steven Kuppens
    Rajesh Bandekar
    Pamela L. Clemens
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Craig C. Hofmeister
    Leukemia, 2020, 34 : 1840 - 1852
  • [6] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Landgren, C. Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter
    Estell, Jane A.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Catherine
    Cavo, Michele
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Kuppens, Steven
    Bandekar, Rajesh
    Clemens, Pamela L.
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Hofmeister, Craig C.
    LEUKEMIA, 2020, 34 (07) : 1840 - 1852
  • [7] Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    Grosicki, Sebastian
    Vorobyev, Vladimir I.
    Spicka, Ivan
    Hungria, Vania T. M.
    Korenkova, Sibirina
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin F.
    Iida, Shinsuke
    Laubach, Jacob P.
    Masterson, Tara
    Lantz, Kristen Anne
    O'Rourke, Lisa
    Heuck, Christoph
    Qin, Xiang
    Parasrampuria, Dolly A.
    Qi, Ming
    Bahlis, Nizar
    BLOOD, 2019, 134
  • [8] Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
    Mateos, Maria-Victoria
    Nahi, Hareth
    Legiec, Wojciech
    Grosicki, Sebastian
    Vorobyev, Vladimir
    Spicka, Ivan
    Hungria, Vania T. M.
    Korenkova, Sibirina
    Bahlis, Nizar J.
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin
    Iida, Shinsuke
    Laubach, Jacob
    Ahmadi, Tahamtan
    Parasrampuria, Dolly A.
    Peng, Lixian
    Qi, Ming
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
    Landgren, Ola
    Cavo, Michele
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter M.
    Estell, Jane
    Sandhu, Irwindeep
    Jenner, Matthew
    Williams, Catherine
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Goldschmidt, Hartmut
    Moreau, Philippe
    Kuppens, Steven
    Bandekar, Rajesh
    Neff, Tobias
    Cortoos, Annelore
    Clemens, Pamela L.
    Qi, Ming
    Adams, Homer, III
    Hofmeister, Craig C.
    BLOOD, 2018, 132
  • [10] Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with IntermediateRisk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study
    Landgren, Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter M.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Smith, Dean
    Cavo, Michele
    van de Donk, Niels Wcj
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Sha, Linlin
    Li, Liang
    Rousseau, Els
    Dennis, Robyn
    Carson, Robin
    Hofmeister, Craig C.
    BLOOD, 2023, 142
12345